AZ
Head-to-head boost for Brilinta over Plavix
September 4, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has released details of its brand Brilinta’s performance in head-to-head trials with Plavix, the world’s second biggest-selling drug.Earlier this …
US approval for Onglyza
August 6, 2009Research and Development, Sales and Marketing AZ, BMA, diabetes
Adult type II diabetes treatment Onglyza has been approved by the US Food and Drug Administration. Co-marketed by AstraZeneca and …
Crestor drives positive results for AZ
July 31, 2009Sales and Marketing AZ, Crestor
AstraZeneca delivered a solid second quarter performance thanks to US delays to generic rivals and strong Crestor sales. The results …
Onglyza and Cimzia recommended by CHMP
July 2, 2009Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza
Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …
AZ research collaboration targets cancer ‘chaperones’
June 8, 2009Research and Development AZ, Academic
AstraZeneca is putting more than £4 million over the next three years into an oncology research project with two partners. …
AstraZeneca and Merck launch early stage trial collaboration
June 3, 2009Research and Development AZ, AstraZeneca, Cancer, Merck
Merck and AstraZeneca have begun an unprecedented collaboration to bring together the clinical trials of two early stage cancer medicines.The …
AstraZeneca buoyed as Brilinta tops Plavix in trial
May 13, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has been lifted by clinical results indicating its antiplatelet drug Brilinta outperformed Sanofi-Aventis/Bristol-Myers Squibb’s Plavix – currently the world’s …
AZ’s Iressa to make comeback
April 28, 2009Research and Development, Sales and Marketing AZ, Iressa
AstraZeneca's Iressa is set to make a comeback after a European committee recommended its use for a sub-group of lung …
AZ shuns mega-mergers but still open to smaller deals
April 21, 2009Research and Development, Sales and Marketing AZ
AstraZeneca will not follow this year's emerging pharma trend towards mega-mergers and may instead look to smaller-scale deals, according to …
Committee approves limited use of Seroquel in depression
April 9, 2009Research and Development, Sales and Marketing AZ, Seroquel, US
An FDA advisory committee has concluded that safety concerns mean that Seroquel XR should not be used to treat anxiety, …
AstraZeneca to cut more jobs as sales stagnate
January 30, 2009Sales and Marketing AZ, restructure
AstraZeneca's revenues will see virtually no growth in 2009, and the company has extended its cost cutting programme. Chief executive …
Pharma could be top performer in recession, says AZ chief
December 4, 2008Sales and Marketing AZ, hc
AstraZeneca's chief executive David Brennan says the pharmaceutical industry could be one of the top performing sectors during the global …
AZ to cut 1,400 manufacturing and supply chain jobs
November 21, 2008Manufacturing and Production AZ
AstraZeneca has announced the loss of 1,400 jobs in its European manufacturing and supply chain infrastructure.The company says the introduction …
Emerging markets shine for AstraZeneca
November 6, 2008Sales and Marketing AZ, China, hc
AstraZeneca saw overall sales for the three months to September rise 3% to $7.8 billion. But growth in emerging markets …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
